{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:53:13Z","timestamp":1765961593446,"version":"3.45.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jtocrr.2022.100424","type":"journal-article","created":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T03:27:15Z","timestamp":1665804435000},"page":"100424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A\u00a0Single-Arm, Open-Label, Phase 2 Clinical Trial"],"prefix":"10.1016","volume":"3","author":[{"given":"Makoto","family":"Hibino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Hiranuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshizumi","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Chihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taishi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Kita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyo","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Shiotsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshie","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2022.100424_bib1","first-page":"48","article-title":"Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update","volume":"2","author":"Bethune","year":"2010","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.jtocrr.2022.100424_bib2","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1200\/JCO.2010.31.8923","article-title":"American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy","volume":"29","author":"Keedy","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2022.100424_bib3","first-page":"2800","article-title":"EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: A Polish, single institution study and systematic review of European incidence","volume":"6","author":"Szumera-Cie\u0107kiewicz","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.jtocrr.2022.100424_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/jclinpath-2012-201194","article-title":"EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples","volume":"66","author":"Ellison","year":"2013","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.jtocrr.2022.100424_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/bjc.2013.721","article-title":"First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study","volume":"110","author":"Douillard","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtocrr.2022.100424_bib6","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2022.100424_bib7","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1200\/JCO.2010.32.6181","article-title":"Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas","volume":"29","author":"D\u2019Angelo","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2022.100424_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jtocrr.2022.100424_bib9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A\u00a0prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (Pioneer)","volume":"9","author":"Shi","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2022.100424_bib10","unstructured":"National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice Guidelines in oncology, non-small cell lung cancer, version 3.2020. https:\/\/www2.tri-kobe.org\/nccn\/guideline\/lung\/english\/non_small.pdf. Accessed September 1, 2020."},{"key":"10.1016\/j.jtocrr.2022.100424_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2022.100424_bib12","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtocrr.2022.100424_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.lungcan.2019.09.019","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study","volume":"137","author":"Mehlman","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2022.100424_bib14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lungcan.2020.11.020","article-title":"Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: survival follow-up results of the randomized JO25567 study","volume":"151","author":"Yamamoto","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2022.100424_bib15","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","article-title":"Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study","volume":"39","author":"Zhou","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtocrr.2022.100424_bib16","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2022.100424_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2022.100424_bib18","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1111\/1759-7714.14541","article-title":"Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: exploratory subgroup analyses from the phase II JO25567 study","volume":"13","author":"Hosomi","year":"2022","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtocrr.2022.100424_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11912-013-0315-7","article-title":"The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion","volume":"15","author":"Bradshaw","year":"2013","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jtocrr.2022.100424_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/etm_00000001","article-title":"The angiogenetic pathway in malignant pleural effusions: pathogenetic and therapeutic implications","volume":"1","author":"Economidou","year":"2010","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jtocrr.2022.100424_bib21","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-08-2904","article-title":"Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance","volume":"15","author":"Naumov","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2022.100424_bib22","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3390\/biomedicines9101327","article-title":"Concurrent blockade of endothelial EGFR and VEGF signaling on malignant associated pleural fluid induced angiogenesis: from clinic to bench","volume":"9","author":"Chen","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jtocrr.2022.100424_bib23","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jtho.2022.05.006","article-title":"Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations; WJOG9717L study","volume":"17","author":"Kenmotsu","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2022.100424_bib24","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamaoncol.2020.1260","article-title":"Effect of Osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: a Phase 1\/2 single-group open-label trial","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtocrr.2022.100424_bib25","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"152","author":"Schulz","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtocrr.2022.100424_bib26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline. version 1.1","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2022.100424_bib27","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2022.100424_bib28","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events. version 5.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5.0.xlsx. Accessed September 1, 2020."},{"key":"10.1016\/j.jtocrr.2022.100424_bib29","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.2217\/fon-2016-0163","article-title":"Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two phase II studies","volume":"12","author":"Atagi","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtocrr.2022.100424_bib30","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10654-008-9278-7","article-title":"Survival analysis: up from Kaplan-Meier-Greenwood","volume":"23","author":"Miettinen","year":"2008","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jtocrr.2022.100424_bib31","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2022.100424_bib32","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AUR A study phase II extension component","volume":"35","author":"Yang","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2022.100424_bib33","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Goss","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2022.100424_bib34","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/j.cllc.2019.03.002","article-title":"Phase I\/II study of osimertinib with bevacizumab in EGFR-mutated, T790M-positive patients with progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L)","volume":"20","author":"Akamatsu","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2022.100424_bib35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.annonc.2021.11.010","article-title":"A\u00a0randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10\u201316) BOOSTER trial","volume":"33","author":"Soo","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2022.100424_bib36","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1172\/JCI79840","article-title":"Mast cells mediate malignant pleural effusion formation","volume":"125","author":"Giannou","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtocrr.2022.100424_bib37","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12967-022-03331-9","article-title":"Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer","volume":"20","author":"Yi","year":"2022","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jtocrr.2022.100424_bib38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.21037\/tlcr-20-893","article-title":"Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma","volume":"10","author":"Kang","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtocrr.2022.100424_bib39","doi-asserted-by":"crossref","first-page":"8273","DOI":"10.2147\/OTT.S271011","article-title":"High PD-L1 expression is associated with unfavorable clinical outcome in EGFR-mutated lung adenocarcinomas treated with targeted therapy","volume":"13","author":"Yoon","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jtocrr.2022.100424_bib40","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/1078-0432.CCR-18-1102","article-title":"Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers","volume":"25","author":"Offin","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2022.100424_bib41","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3389\/fonc.2020.00480","article-title":"Tumor mutation burden correlates with efficacy of chemotherapy\/targeted therapy in advanced non-small cell lung cancer","volume":"10","author":"Lin","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtocrr.2022.100424_bib42","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cllc.2021.09.004","article-title":"Impact of tumor suppressor gene co-mutations on differential response to EGFR TKI therapy in EGFR L858R and Exon 19 deletion lung cancer","volume":"23","author":"Hellyer","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2022.100424_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.610923","article-title":"Concurrent genetic alterations and other biomarkers predict treatment efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer: a review","volume":"10","author":"Guo","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtocrr.2022.100424_bib44","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/1759-7714.13738","article-title":"Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: a phase II single-arm prospective clinical trial","volume":"12","author":"Lu","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtocrr.2022.100424_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100507","article-title":"Impact of smoking status on the relative efficacy of the EGFR TKI\/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis","volume":"7","author":"Dafni","year":"2022","journal-title":"ESMO Open"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364322001485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364322001485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:37:57Z","timestamp":1762987077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364322001485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2666364322001485"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100424","relation":{},"ISSN":["2666-3643"],"issn-type":[{"type":"print","value":"2666-3643"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A\u00a0Single-Arm, Open-Label, Phase 2 Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100424"}}